EP2895508A1 - Inhibiteurs des interactions de liaison de la sous-unité alpha de protéine g-intégrine bêta - Google Patents

Inhibiteurs des interactions de liaison de la sous-unité alpha de protéine g-intégrine bêta

Info

Publication number
EP2895508A1
EP2895508A1 EP13783707.6A EP13783707A EP2895508A1 EP 2895508 A1 EP2895508 A1 EP 2895508A1 EP 13783707 A EP13783707 A EP 13783707A EP 2895508 A1 EP2895508 A1 EP 2895508A1
Authority
EP
European Patent Office
Prior art keywords
peptide
integrin
seq
antibody
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13783707.6A
Other languages
German (de)
English (en)
Inventor
Xiaoping Du
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois
Original Assignee
University of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/621,064 external-priority patent/US8685921B2/en
Application filed by University of Illinois filed Critical University of Illinois
Publication of EP2895508A1 publication Critical patent/EP2895508A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés qui inhibent une interaction de liaison entre une intégrine β et une sous-unité de protéine G, ainsi que des compositions, par exemple des compositions pharmaceutiques, comportant celles-ci, et des nécessaires associés. Dans certains modes de réalisation, le composé est un anticorps ou un analogue d'anticorps et, dans d'autres modes de réalisation, le composé est un peptide ou un analogue de peptide. L'invention concerne également des procédés d'utilisation des composés, comprenant des méthodes de traitement ou de prévention d'un état médical, tel qu'un accident vasculaire cérébral, une crise cardiaque, le cancer ou une inflammation.
EP13783707.6A 2012-09-15 2013-09-13 Inhibiteurs des interactions de liaison de la sous-unité alpha de protéine g-intégrine bêta Withdrawn EP2895508A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/621,064 US8685921B2 (en) 2010-03-15 2012-09-15 Inhibitors of beta integrin-G protein alpha subunit binding interactions
PCT/US2013/059833 WO2014043594A1 (fr) 2010-03-15 2013-09-13 Inhibiteurs des interactions de liaison de la sous-unité alpha de protéine g-intégrine bêta

Publications (1)

Publication Number Publication Date
EP2895508A1 true EP2895508A1 (fr) 2015-07-22

Family

ID=49510486

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13783707.6A Withdrawn EP2895508A1 (fr) 2012-09-15 2013-09-13 Inhibiteurs des interactions de liaison de la sous-unité alpha de protéine g-intégrine bêta

Country Status (2)

Country Link
EP (1) EP2895508A1 (fr)
CN (1) CN104995207B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106226535B (zh) * 2016-08-01 2018-03-09 中国科学院广州生物医药与健康研究院 Cd61作为生血内皮细胞标志物的用途
US20200128819A1 (en) * 2017-06-13 2020-04-30 Croda, Inc. Agrochemical electrolyte compositions
WO2022183360A1 (fr) * 2021-03-02 2022-09-09 Tsao Yeou Ping Peptides synthétiques courts et leurs utilisations pour le traitement de la sécheresse oculaire
CN113171440A (zh) * 2021-04-26 2021-07-27 石家庄喜得宝医疗器械有限公司 一种生物蛋白敷料组合物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2547359B1 (fr) * 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Inhibiteurs des interactions de liaison de sous unité alpha d'intégrine à-de protéine g

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2014043594A1 *

Also Published As

Publication number Publication date
CN104995207A (zh) 2015-10-21
CN104995207B (zh) 2018-08-07

Similar Documents

Publication Publication Date Title
US20210054026A1 (en) Inhibitors of Beta Integrin-G Protein Alpha Subunit Binding Interactions
US9029502B2 (en) Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
US11827712B2 (en) IL13Rα2 binding agents and use thereof
EP3250611B1 (fr) Lymphocytes t à récepteur d'antigène chimérique (car) reconnaissant le récepteur il 13r-alpha2 spécifique au cancer
BR112020017709A2 (pt) Anticorpo anti-sirpa humana, fragmento de ligação a antígeno do mesmo ou anticorpo modificado do mesmo, composição farmacêutica, uso de um polipeptídeo, métodos para preparar um anticorpo anti-sirpa humana v1, para aumentar a apresentação cruzada de um antígeno e para avaliar a probabilidade de eficácia de um tratamento, método in vitro ou ex vivo para avaliar a probabilidade de eficácia de um tratamento, e, combinação de compostos
JP2020055885A (ja) 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
US10611798B2 (en) PAR1 and PAR2 c-tail peptides and peptide mimetics
JP2016539121A (ja) 血管新生抑制活性を有するペプチド、及びそれを含む組成物
US20220056150A1 (en) Anti-factor ix padua antibodies
KR20180030898A (ko) Gdf15의 활성 감소용 제제
EP2895508A1 (fr) Inhibiteurs des interactions de liaison de la sous-unité alpha de protéine g-intégrine bêta
JP2021512919A (ja) 異所性骨化を処置するための方法
WO2011080401A1 (fr) Compositions de liaison à un récepteur tyrosine kinase
WO2018112226A1 (fr) Polypeptides à base de sharpin et leurs utilisations
CN108290930A (zh) Pink1 c末端结构域多肽及其用于癌症治疗的方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150414

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160627

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161108